The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
First published in 2017, it disrupts the FOXO4–p53 interaction to trigger apoptosis selectively in senescent cells – an elegant mechanism that made headlines when treated mice showed restored organ function. As of mid-2026 there are no completed or registered human trials; every result comes from mouse models and cell culture.
The full published spec sheet — dose units, timing, frequency, and cycle length — is included with membership.
The published dose for this compound, shown as reference. Included with membership.
Reference values as published in the research record — not a recommendation, instruction, or dose suggestion for any person. Not medical advice.
The live calculator — enter any vial size, diluent volume, and syringe size to see the draw computed — is included with membership.